caa a22 4500 445298863 CHVBK 20180317142551.0 cr unu---uuuuu 170323e20100101xx s 000 0 eng 10.1007/s11940-009-0055-z doi (NATIONALLICENCE)springer-10.1007/s11940-009-0055-z Myotonia Congenita and Myotonic Dystrophy: Surveillance and Management [Elektronische Daten] [Allison Conravey, Lenay Santana-Gould] Opinion statement: Myotonia can be treated both pharmacologically and by lifestyle modifications. Cell membrane stabilizers are the medications most commonly used for symptomatic treatment of myotonia. Most patients do not require treatment for the myotonia itself, unless it is severe, but physicians must be aware of anesthesia risks in both myotonia congenita and myotonic dystrophy. A mainstay of management of myotonic dystrophy is the surveillance and treatment of its various systemic complications. Springer Science+Business Media, LLC, 2010 Conravey Allison Department of Pediatrics, Tulane University, 1430 Tulane Avenue, SL-37, 70112, New Orleans, LA, USA aut Santana-Gould Lenay Department of Pediatrics, Tulane University, 1430 Tulane Avenue, SL-37, 70112, New Orleans, LA, USA aut Current Treatment Options in Neurology Current Science Inc. 12/1(2010-01-01), 16-28 1092-8480 12:1<16 2010 12 11940 https://doi.org/10.1007/s11940-009-0055-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11940-009-0055-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Conravey Allison Department of Pediatrics, Tulane University, 1430 Tulane Avenue, SL-37, 70112, New Orleans, LA, USA aut NATIONALLICENCE 700 1- Santana-Gould Lenay Department of Pediatrics, Tulane University, 1430 Tulane Avenue, SL-37, 70112, New Orleans, LA, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Neurology Current Science Inc 12/1(2010-01-01), 16-28 1092-8480 12:1<16 2010 12 11940 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer